- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05397106
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
Post-Market Clinical Follow-up of Patients With CODMAN CERTAS Plus Programmable Valve
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The CODMAN CERTAS Plus Programmable Valve is a single use implantable device designed for shunting cerebrospinal fluid (CSF) for the treatment of hydrocephalus.
The valve can be set to 8 different performance settings for intraventricular pressure and drainage of CSF. The performance setting of the valve can be set preoperatively and can also be noninvasively changed post-implantation.
This clinical investigation will maintain data for each patient from the date of implant through 3 years post-implantation.
Data collection for each patient will occur per standard of care.
However, the clinical investigation specifically aims to collect and analyze data from the day of procedure, and post-operatively at 1 month, 3 months, 6 months, 12 months, 24 months, and 36 months.
Data from follow-up visits will be analyzed according to pre-defined time-intervals referring to these follow-up moments.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Maria Salmon-Sargeant
- Phone Number: 339-206-2979
- Email: maria.salmonsargeant@integralife.com
Study Contact Backup
- Name: Andrew Tummon
- Phone Number: 1-609-936-5490
- Email: Andrew.Tummon@integralife.com
Study Locations
-
-
-
Roeselare, Belgium
- Not yet recruiting
- AZ Delta - Roeselare
-
Contact:
- Dimitri Vanhauwaert, MD
- Phone Number: + 32 51 237440
- Email: dimitri.vanhauwaert@azdelta.be
-
Contact:
- Stijn Van Damme, SC
- Phone Number: + 32 51 237449
- Email: stijn.vandamme@azdelta.be
-
-
-
-
-
Dortmund, Germany
- Recruiting
- Klinikum Dortmund Wirbelsäulenchirurgie
-
Contact:
- Dr. Oliver Müller
-
Düsseldorf, Germany, 40225
- Not yet recruiting
- Heinrich Heine University, Dept of Neurosurgery, Universitätsklinik Düsseldorf
-
Contact:
- Thomas Beez, MD
- Phone Number: +49 211 81 07664
- Email: thomas.beez@med.uni-duesseldorf.de
-
Contact:
- Fljamur Aljiji, SC
- Email: Fljamur.Aljiji@med.uni-duesseldorf.de
-
Essen, Germany
- Recruiting
- Universitätsklinikum Essen
-
Contact:
- Dr. Philipp Dammann
-
Freiburg, Germany
- Recruiting
- Freiburg University Hospital
-
Contact:
- Dr. Mukesch Johannes Shah
-
Stuttgart, Germany
- Recruiting
- Katharinenhospital - Neurochirurgische Klinik Stuttgart
-
Contact:
- Dr. Oliver Gandslandt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Consecutive patients of any age, gender, and ethnicity, with hydrocephalus.
Patients will receive the CODMAN CERTAS Plus Programmable Valve type most applicable for their condition, as determined by their clinician.
Description
Inclusion Criteria:
- Patient and/or legally authorized representative has agreed to participate in the study by signing the EC-approved consent form, where applicable.
- Patients (of any age) who underwent or who plan to have a surgical procedure utilizing one of the Codman CERTAS Plus Programmable Valves.
- Patient (legally designated representative) is willing to comply with the study protocol timelines & requirements.
- For patients who have had the Codman CERTAS Plus Programmable Valve implanted prior to study enrollment, have available data from implantation to the current time.
Exclusion Criteria:
- Patients undergoing implantation of the CODMAN CERTAS Plus Programmable Valve as a revision procedure.
- Patient's planned shunt has distal drainage to the heart.
- Patient has ventriculitis, peritonitis or meningitis.
- Patient has sepsis.
- Patient has a history of poor wound healing.
- Patient has symptoms pertaining to a skin infection at or near the site of any incisions; an ear infection on either side; a respiratory tract infection; or a urinary tract infection that, in the Investigator's opinion is clinically significant and might compromise the outcome of this study.
- Patient has had any form of bowel surgery 30 days prior to device implant or anticipates bowel surgery within 90 days following device implant.
- Patient is otherwise determined by the Investigator to be medically unsuitable for participation in this study.
- Patient is currently enrolled in another drug or device trial or has been previously entered in this trial.
- Patient is a prisoner or member of a different vulnerable population that should not be included in the study per the investigator.
- Patients with known hypersensitivity to rifampin or clindamycin hydrochloride. This criterion applies for patients to be treated with the BACTISEAL Catheters (included in some models of the valve) only.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CODMAN CERTAS Programmable Valves
CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
|
Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device success - Time Frame: Days
Time Frame: 30 Days
|
Device Success is defined as:
|
30 Days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Valve Replacement
Time Frame: 12, 24 and 36 Months
|
Incidence of Valve replacement post - implantation
|
12, 24 and 36 Months
|
Adverse Events
Time Frame: 12, 24 and 36 Months
|
Incidence of Adverse Events post - implantation Long term safety will be assessed by the incidence of all adverse events/complications including number of subjects with shunt and/or shunt system infections. |
12, 24 and 36 Months
|
Number of encounters with inadvertent reprogramming of CODMAN CERTAS Plus Programmable Valves
Time Frame: 12, 24 and 36 Months
|
Incidence of inadvertent reprogramming of CODMAN CERTAS Plus Programmable Valves post - implantation prior to MRI
|
12, 24 and 36 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sherese Fralin, MSN, FNP, PhD, Integra LifeSciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-CERTAS-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Tumor
-
University of California, San FranciscoGilead SciencesSuspendedBrain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, PediatricUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...CNOG-MC001 Collaborative GroupCompletedPediatric Brain Tumor | Malignant Brain Tumor | Tumors, Central Nervous System | Benign Brain TumorChina
-
Technical University of MunichRecruiting
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
Washington University School of MedicineNot yet recruitingBrain Tumor, PrimaryUnited States
-
GT Medical Technologies, Inc.RecruitingBrain Tumor | Brain Tumor, Recurrent | Brain Tumor, Primary | Brain Tumor - Metastatic | Brain Tumor, Adult: Glioblastoma | Brain Tumor, Adult MeningiomaUnited States
-
The Hospital for Sick ChildrenPediatric Oncology Group of OntarioCompletedChildhood Brain TumorCanada
-
Ohio State University Comprehensive Cancer CenterCompletedAdult Brain TumorUnited States
-
Lawson Health Research InstituteCompletedBrain Tumor | Brain Neoplasm | Tumor, Brain | Neoplasm, Supratentorial | Tumor, SupratentorialCanada
Clinical Trials on CODMAN CERTAS Plus Programmable Valve
-
Integra LifeSciences CorporationAvaniaCompletedHydrocephalus | NPH (Normal Pressure Hydrocephalus) | IIH - Idiopathic Intracranial HypertensionGermany, Netherlands
-
University Hospital, LinkoepingActive, not recruitingHydrocephalus, Normal Pressure | Ventriculomegaly, Cerebral | Shunt; Complications | Hydrocephalus AcquiredSweden
-
Johns Hopkins UniversityUniversity of Utah; Integra LifeSciences CorporationCompletedIdiopathic Normal Pressure Hydrocephalus (INPH)United States, Canada, Sweden
-
Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingIdiopathic Normal Pressure Hydrocephalus (INPH)United States, Canada, Sweden
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanCompletedHydrocephalus | Ventriculoperitoneal Shunt Malfunction
-
University of California, IrvineTerminatedNormal Pressure HydrocephalusUnited States
-
Swan Medical S. L.TerminatedStenosis | Regurgitation, AorticSpain
-
SOLX, Inc.SuspendedGlaucoma | Glaucoma, Open AngleUnited States, Israel, Canada, India, Poland
-
Khon Kaen UniversityCompletedCritically Ill Patients | Catheter Associated Urinary Tract InfectionThailand
-
Johns Hopkins UniversityTerminated